Marshall Wace North America’s Kyntra Bio KYNB Stock Holding History

Marshall Wace North America’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,268	Closed	-$1.3M	–	1388
2020 Q3	$1.3M	Buy	+1,268	New	+$1.36M	0.01%	725
2020 Q1	–	Sell	-113	Closed	-$121K	–	1350
2019 Q4	$121K	Sell	113 -963	-89%	-$983K	﹤0.01%	1037
2019 Q3	$995K	Buy	+1,076	New	+$1.18M	0.01%	699
2019 Q1	–	Sell	-1,494	Closed	-$2.03M	–	1667
2018 Q4	$1.73M	Buy	+1,494	New	+$1.68M	0.02%	455
2018 Q1	–	Sell	-1,526	Closed	-$1.81M	–	1516
2017 Q4	$1.81M	Sell	1,526 -1,133	-43%	-$1.42M	0.01%	857
2017 Q3	$3.59M	Buy	+2,659	New	+$2.8M	0.02%	640

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Marshall Wace North America's KYNB Position: Q4 2020 in Review

Marshall Wace North America sold out of Kyntra Bio (KYNB) in Q4 2020, closing a stake of 1,268 shares — an estimated $1.3M sold.

Marshall Wace North America first reported a position in KYNB in Q3 2017 and held it in 6 quarters. The position peaked at $3.59M in Q3 2017. 207 funds tracked by Wall St. Rank hold KYNB as of Q4 2020.

Marshall Wace North America reported no remaining Kyntra Bio position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 1,268 Kyntra Bio shares in Q4 2020, an estimated $1.3M.
Marshall Wace North America first reported a position in Kyntra Bio in Q3 2017 and held it in 6 quarters.
Marshall Wace North America's Kyntra Bio position peaked at $3.59M in Q3 2017.
207 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.